Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: J Steroid Biochem Mol Biol. 2020 Mar 3;200:105650. doi: 10.1016/j.jsbmb.2020.105650

Figure 5: Increases in muscle CYP27B1 mRNA in ALS patients correlate with rate of disease progression.

Figure 5:

(A) CYP27B1 mRNA levels were determined by qPCR in serial muscle biopsy samples from 8 ALS patients over a 6 to 12-month time period (see Table 3). ALS4 declined biopsy at the 12-month interval and ALS 5 had insufficient tissue for RNA analysis at 6 months. The monthly decline in the ALSFRS-R (ΔFRS) is shown. The change in CYP27B1 mRNA over time was estimated by the slope (m). In patients that had 3 data points, the slope was estimated using linear regression. (B) Correlation plot of CYP27B1 slopes from (A) versus ΔFRS for the study period. (C) Mean (± SD) CYP27B1 mRNA levels in two serial muscle biopsies from seven neurologically normal controls over an average of 9 months. (D) Mean (± SD) values of CYP27B1 mRNA levels of ALS patients and controls at baseline and at the end of the study. *P < 0.05.